Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“assessed using a modified semiquantitative Brunt score [15].”
MethodCani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819 · cited 8×
“Animals started therapy after NAFLD/NASH had become established.”
InfluentialSteatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · cited 2×
“Given that translocation of bacterial LPS across the intestinal wall and subsequent passage along the portal vein to the liver has previously been suggested as an important ‘second-hit’ in the pathogenesis of steatohepatitis [1,2,35], the changes in gut flora and mucosal permeability that may be induced by PEG are lik…”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“The recently published multi-centre PIVENS trial has shown it to reduce biochemical and histological steatohepatitis in clinical practice [30].”
BackgroundMofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085 · cited 2×
“In livers from NASH patients it has been shown that apoptosis is frequently triggered through activation of Fas receptors [6].”
BackgroundIredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 1×
“Resolution of fibrosis involves apoptotic clearance of activated fibrogenic hepatic stellate cells [26,27] therefore caspase inhibition during this time could theoretically impede resolution of established disease.”
BackgroundDumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042 · cited 8×
“Animals started therapy after NAFLD/NASH had become established.”
InfluentialModels of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866 · cited 1×
“Resolution of fibrosis involves apoptotic clearance of activated fibrogenic hepatic stellate cells [26,27] therefore caspase inhibition during this time could theoretically impede resolution of established disease.”
BackgroundFeldstein, A. E., Werneburg, N. W., Canbay, A., Guicciardi, M. E., Bronk, S. F., Rydzewski, R., Burgart, L. J., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20283 · Cited by 834
Cited by
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citationCell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Self-citationApoptosis and necroptosis in the liver: a matter of life and death
Schwabe, R. F., & Luedde, T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0065-y · Cited by 582
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
The applications of Vitamin E TPGS in drug delivery
Guo, Y., Luo, J., Tan, S., Otieno, B. O., & Zhang, Z. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.02.006 · Cited by 523
Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes
Hirsova, P., Ibrahim, S. H., Krishnan, A., Verma, V. K., Bronk, S. F., Werneburg, N. W., Charlton, M. R., Shah, V. H., Malhi, H., & Gores, G. J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.037 · Cited by 507
Anstee, Q. M., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.182 · Cited by 333
Self-citationA positive feedback loop between RIP3 and JNK controls non‐alcoholic steatohepatitis
Gautheron, J., Vucur, M., Reisinger, F., Cardenas, D. V., Roderburg, C., Koppe, C., Kreggenwinkel, K., Schneider, A. T., Bartneck, M., Neumann, U. P., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403856 · Cited by 314
Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313
“1) include loss of CK18 immunostaining(28,29) and Mallory-Denk bodies.”
Self-citationAbsence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury
Roychowdhury, S., McMullen, M. R., Pisano, S. G., Liu, X., & Nagy, L. E. (2013) · Hepatology · doi:10.1002/hep.26200 · Cited by 304
Barreyro, F. J., Holod, S., Finocchietto, P. V., Camino, A. M., Aquino, J. B., Avagnina, A., Carreras, M. C., Poderoso, J. J., & Gores, G. J. (2015) · Liver International · doi:10.1111/liv.12570 · Cited by 294
Cell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 293
Yamada, T., Murata, D., Adachi, Y., Itoh, K., Kameoka, S., Igarashi, A., Kato, T., Araki, Y., Huganir, R. L., Dawson, T. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.014 · Cited by 290
Li, X., Wang, T., Huang, X., Li, Y., Sun, T., Zang, S., Guan, K., Xiong, Y., Liu, J., & Yuan, H. (2020) · Liver International · doi:10.1111/liv.14428 · Cited by 273
Apoptosis and non-alcoholic fatty liver diseases
Kanda, T., Matsuoka, S., Yamazaki, M., Shibata, T., Nirei, K., Takahashi, H., Kaneko, T., Fujisawa, M., Higuchi, T., Nakamura, H., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2661 · Cited by 270
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications
Alkhouri, N., Carter-Kent, C., & Feldstein, A. E. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.6 · Cited by 254
Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 219
The epidemiology, pathogenesis and histopathology of fatty liver disease
Levene, A. P., & Goldin, R. D. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04145.x · Cited by 192
Self-citationInflammasomes in liver fibrosis
Alegre, F., Pelegrin, P., & Feldstein, A. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1601350 · Cited by 176
Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
Wan, X., Xu, C., Yu, C., & Li, Y. (2016) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2016/6489012 · Cited by 174
“Another study reported that, in both models (HFD and MCD), VX-166 did not reduce steatosis but reduced hepatic apoptosis, histological inflammation, serum ALT levels, and oxidative stress [16].”
Thapaliya, S., Wree, A., Povero, D., Inzaugarat, M. E., Berk, M., Dixon, L., Papouchado, B. G., & Feldstein, A. E. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3167-6 · Cited by 162
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Zhou, J., Huang, N., Guo, Y., Cui, S., Ge, C., He, Q., Pan, X., Wang, G., Wang, H., & Hao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.004 · Cited by 99
Infiltrating monocytes in liver injury and repair
Brempelis, K. J., & Crispe, I. N. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.62 · Cited by 97
Liu, D., Wang, K., Li, K., Xu, R., Chang, X., Zhu, Y., Sun, P., & Han, X. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1672-4 · Cited by 35
Metadata
- Authors
- Anstee, Q. M., Concas, D., Kudo, H., Levene, A., Pollard, J., Charlton, P., Thomas, H. C., Thursz, M. R., & Goldin, R. D.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 53
- Issue
- 3
- Pages
- 542-550
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1989653785
- Cited by
- 158
- References
- 35
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.